<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-09-16" updated="2020-01-02">
  <drugbank-id primary="true">DB09107</drugbank-id>
  <drugbank-id>DB06279</drugbank-id>
  <name>Methoxy polyethylene glycol-epoetin beta</name>
  <description>Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to  treat chronic kidney disease associated anemia.</description>
  <cas-number>677324-53-7</cas-number>
  <unii>LR3UXN0193</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18823</ref-id>
        <pubmed-id>15358619</pubmed-id>
        <citation>Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P: Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood. 2005 Jan 15;105(2):600-8. Epub 2004 Sep 9.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L495</ref-id>
        <title>Daily Med Micera Monograph</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c6b7448-152f-435f-a672-7404b1bfe7eb</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.</indication>
  <pharmacodynamics>Stimulates hemoglobin production by stimulating the erythropoetin receptor of erythroid progenitor cells in the bone marrow. Hemoglobin increase, following a single initial dose, occurs 7 to 15 days after.</pharmacodynamics>
  <mechanism-of-action>Erythropoietin is a growth factor for erythroid development. It is produced in the kidney and released into the bloodstream in response to hypoxia, interacting with erythroid progenitor cells to increase red blood cell production. Production of endogenous erythropoietin is impaired in patients with chronic kidney disease (CKD), and erythropoietin deficiency is the primary cause of their anaemia. Administration of methoxy polyethylene glycol-epoetin beta acts like endogenous erythropoetin and stimulates erythropoetin receptor of the erythroid progenitor cells in the bone marrow.</mechanism-of-action>
  <toxicity>Overdosage can cause severe hypertension.</toxicity>
  <metabolism>Not metabolized. </metabolism>
  <absorption>Administered parenterally (subcutaneous or IV) therefore not absorbed.</absorption>
  <half-life>In CKD patients on peritoneal dialysis with IV administration: 134 ± 65 hours&#13;
In CKD patients on peritoneal dialysis with SC administration: 139 ± 67 hours</half-life>
  <protein-binding>No protein binding</protein-binding>
  <route-of-elimination>Undergoes proteolysis at erythropoietin receptor </route-of-elimination>
  <volume-of-distribution>~94.74 ml/kg</volume-of-distribution>
  <clearance>In CKD patients on peritoneal dialysis : 0.49 ± 0.18 mL/hr/kg&#13;
</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">CERA</synonym>
    <synonym language="english" coder="">Pegzerepoetin alfa</synonym>
  </synonyms>
  <products>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/008</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/009</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/010</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/011</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/012</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/013</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>250 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/017</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/018</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/019</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/020</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>120 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/021</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>360 μg/0.6ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/022</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/023</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Roche Registration Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000739</ema-product-code>
      <ema-ma-number>EU/1/07/400/024</ema-ma-number>
      <started-marketing-on>2007-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 μg/0.3ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on>2019-05-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>250 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>120 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>250 ug/0.3mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Vifor (International) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59353-408</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>360 ug/0.6mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125164</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308061</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308088</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>75 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308096</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>150 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308126</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308134</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>250 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02307995</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308002</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308010</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308029</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>300 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308037</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>400 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308045</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>600 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308053</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1000 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308142</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>400 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mircera</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308150</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>600 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
    <mixture>
      <name>Mircera</name>
      <ingredients>Methoxy polyethylene glycol-epoetin beta</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antianemic Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Erythropoiesis-Stimulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Hematinics</category>
      <mesh-id>D006397</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Increased Erythroid Cell Production</category>
      <mesh-id/>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Pegylated agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>100 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>120 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>150 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>200 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>250 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>30 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>360 ug/0.6mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>50 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>75 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>120 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>250 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>360 μg/0.6ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>50 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>75 μg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>1000 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>250 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>400 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>50 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>600 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>75 mcg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B03XA03">
      <level code="B03XA">Other antianemic preparations</level>
      <level code="B03X">OTHER ANTIANEMIC PREPARATIONS</level>
      <level code="B03">ANTIANEMIC PREPARATIONS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents>
    <patent>
      <number>2310536</number>
      <country>Canada</country>
      <approved>2007-09-11</approved>
      <expires>2020-06-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of Thrombosis can be increased when Peginterferon alfa-2a is combined with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The risk or severity of Thrombosis can be increased when Pegaspargase is combined with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00002</drugbank-id>
      <name>Cetuximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00004</drugbank-id>
      <name>Denileukin diftitox</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00023</drugbank-id>
      <name>Asparaginase Escherichia coli</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Asparaginase Escherichia coli.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Masoprocol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00236</drugbank-id>
      <name>Pipobroman</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pipobroman.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Chlorotrianisene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pamidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bleomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00385</drugbank-id>
      <name>Valrubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valrubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Flutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alitretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nilutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00707</drugbank-id>
      <name>Porfimer sodium</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Porfimer sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00791</drugbank-id>
      <name>Uracil mustard</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Uracil mustard.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00855</drugbank-id>
      <name>Aminolevulinic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aminolevulinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Testolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00947</drugbank-id>
      <name>Fulvestrant</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fulvestrant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00990</drugbank-id>
      <name>Exemestane</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Exemestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Letrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trimetrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Anastrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01269</drugbank-id>
      <name>Panitumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Panitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 8-azaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01873</drugbank-id>
      <name>Epothilone D</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Epothilone D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01933</drugbank-id>
      <name>7-Hydroxystaurosporine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 7-Hydroxystaurosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02109</drugbank-id>
      <name>Hadacidin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Hadacidin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02342</drugbank-id>
      <name>2-Methoxyestradiol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 2-Methoxyestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02424</drugbank-id>
      <name>Geldanamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Geldanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02640</drugbank-id>
      <name>Fumagillin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fumagillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03010</drugbank-id>
      <name>Patupilone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Patupilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03172</drugbank-id>
      <name>Tubercidin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tubercidin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03459</drugbank-id>
      <name>Sparfosic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sparfosic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03496</drugbank-id>
      <name>Alvocidib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alvocidib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03509</drugbank-id>
      <name>2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03695</drugbank-id>
      <name>Piritrexim</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Piritrexim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rhodamine 6G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03880</drugbank-id>
      <name>Batimastat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Batimastat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03946</drugbank-id>
      <name>3,4-Dihydroxybenzoic Acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 3,4-Dihydroxybenzoic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04106</drugbank-id>
      <name>Fotemustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fotemustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04222</drugbank-id>
      <name>Sparsomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sparsomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04253</drugbank-id>
      <name>Tretazicar</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tretazicar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04258</drugbank-id>
      <name>Seocalcitol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Seocalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04331</drugbank-id>
      <name>Monastrol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Monastrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04440</drugbank-id>
      <name>Nebularine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nebularine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04468</drugbank-id>
      <name>Afimoxifene</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Afimoxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04655</drugbank-id>
      <name>Metoprine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Metoprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Camptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04786</drugbank-id>
      <name>Suramin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Suramin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Urethane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04849</drugbank-id>
      <name>Cediranib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cediranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04858</drugbank-id>
      <name>Tirapazamine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tirapazamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04866</drugbank-id>
      <name>Halofuginone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Halofuginone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04894</drugbank-id>
      <name>Vapreotide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vapreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04900</drugbank-id>
      <name>Thymalfasin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Thymalfasin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04901</drugbank-id>
      <name>Galiximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Galiximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04907</drugbank-id>
      <name>Sitimagene ceradenovec</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sitimagene ceradenovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04950</drugbank-id>
      <name>Ranpirnase</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ranpirnase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04958</drugbank-id>
      <name>Epratuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Epratuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04960</drugbank-id>
      <name>Tipifarnib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tipifarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04961</drugbank-id>
      <name>Troxacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Troxacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04964</drugbank-id>
      <name>Oregovomab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04975</drugbank-id>
      <name>Banoxantrone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Banoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04977</drugbank-id>
      <name>Plitidepsin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Plitidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04996</drugbank-id>
      <name>Satraplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Satraplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05022</drugbank-id>
      <name>Amonafide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Amonafide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with SRT501.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05076</drugbank-id>
      <name>Fenretinide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fenretinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05088</drugbank-id>
      <name>Tetrathiomolybdate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tetrathiomolybdate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05097</drugbank-id>
      <name>Labetuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Labetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05129</drugbank-id>
      <name>Elsamitrucin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Elsamitrucin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05136</drugbank-id>
      <name>Bavituximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bavituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05223</drugbank-id>
      <name>Pracinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pracinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cobimetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05265</drugbank-id>
      <name>Ecabet</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ecabet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rindopepimut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05424</drugbank-id>
      <name>Canertinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Canertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05428</drugbank-id>
      <name>Motexafin gadolinium</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Motexafin gadolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05482</drugbank-id>
      <name>7-ethyl-10-hydroxycamptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 7-ethyl-10-hydroxycamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05524</drugbank-id>
      <name>Pelitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pelitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05540</drugbank-id>
      <name>Alanosine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alanosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05578</drugbank-id>
      <name>Ramucirumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ramucirumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05595</drugbank-id>
      <name>Farletuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Farletuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05656</drugbank-id>
      <name>Veltuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Veltuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05668</drugbank-id>
      <name>Palifosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Palifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05697</drugbank-id>
      <name>AP 12009</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with AP 12009.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05779</drugbank-id>
      <name>Oglufanide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oglufanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05786</drugbank-id>
      <name>Irofulven</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Irofulven.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Inotuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05903</drugbank-id>
      <name>KOS-1584</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with KOS-1584.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05916</drugbank-id>
      <name>CT-011</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with CT-011.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05974</drugbank-id>
      <name>Transcrocetinate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Transcrocetinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05996</drugbank-id>
      <name>Glembatumumab vedotin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Glembatumumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06013</drugbank-id>
      <name>Aldoxorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aldoxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06021</drugbank-id>
      <name>AV-412</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with AV-412.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06040</drugbank-id>
      <name>Filanesib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Filanesib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06043</drugbank-id>
      <name>Olaratumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olaratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06159</drugbank-id>
      <name>Rubitecan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rubitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06163</drugbank-id>
      <name>Plevitrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Plevitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06171</drugbank-id>
      <name>Paclitaxel trevatide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel trevatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06181</drugbank-id>
      <name>IMO-2055</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with IMO-2055.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ipilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06192</drugbank-id>
      <name>Nimotuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nimotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06193</drugbank-id>
      <name>Pixantrone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pixantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06195</drugbank-id>
      <name>Seliciclib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Seliciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06199</drugbank-id>
      <name>Atrasentan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Atrasentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06233</drugbank-id>
      <name>Ridaforolimus</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ridaforolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>Exisulind</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Exisulind.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06263</drugbank-id>
      <name>Amrubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Amrubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06266</drugbank-id>
      <name>Lonidamine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lonidamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06272</drugbank-id>
      <name>Maxacalcitol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Maxacalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06317</drugbank-id>
      <name>Elotuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Elotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06334</drugbank-id>
      <name>Tucidinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tucidinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06365</drugbank-id>
      <name>Sapacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sapacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06366</drugbank-id>
      <name>Pertuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pertuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>Annamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Annamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06423</drugbank-id>
      <name>Endostatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Endostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06433</drugbank-id>
      <name>Tezacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tezacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06436</drugbank-id>
      <name>Semaxanib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Semaxanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Diethylnorspermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06461</drugbank-id>
      <name>Squalamine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Squalamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06478</drugbank-id>
      <name>Porfiromycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Porfiromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06517</drugbank-id>
      <name>MLN576</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with MLN576.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06607</drugbank-id>
      <name>Catumaxomab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Catumaxomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Axitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Volociximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06650</drugbank-id>
      <name>Ofatumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ofatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Degarelix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06704</drugbank-id>
      <name>Iobenguane</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Iobenguane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methyltestosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Buserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06748</drugbank-id>
      <name>Ginsenoside C</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ginsenoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06810</drugbank-id>
      <name>Plicamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Plicamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06819</drugbank-id>
      <name>Phenylbutyric acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Phenylbutyric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Triptorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07232</drugbank-id>
      <name>Veliparib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Veliparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Hexestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08313</drugbank-id>
      <name>nocodazole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with nocodazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Puromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08486</drugbank-id>
      <name>Efaproxiral</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Efaproxiral.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08633</drugbank-id>
      <name>TNP-470</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with TNP-470.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabozantinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08885</drugbank-id>
      <name>Aflibercept</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aflibercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08886</drugbank-id>
      <name>Asparaginase Erwinia chrysanthemi</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Formestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trametinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08913</drugbank-id>
      <name>Radium Ra 223 Dichloride</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Radium Ra 223 Dichloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Afatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09010</drugbank-id>
      <name>Carmofur</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carmofur.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09031</drugbank-id>
      <name>Miltefosine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Miltefosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09035</drugbank-id>
      <name>Nivolumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nivolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09037</drugbank-id>
      <name>Pembrolizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pembrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Medrogestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09143</drugbank-id>
      <name>Sonidegib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sonidegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tegafur.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09269</drugbank-id>
      <name>Phenylacetic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Phenylacetic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09274</drugbank-id>
      <name>Artesunate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Artesunate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09298</drugbank-id>
      <name>Silibinin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Silibinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09331</drugbank-id>
      <name>Daratumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Daratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09335</drugbank-id>
      <name>Alatrofloxacin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alatrofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Isosorbide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09559</drugbank-id>
      <name>Necitumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ixazomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11231</drugbank-id>
      <name>Lycopene</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lycopene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11366</drugbank-id>
      <name>Roquinimex</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Roquinimex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11526</drugbank-id>
      <name>Masitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Masitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11595</drugbank-id>
      <name>Atezolizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Atezolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11617</drugbank-id>
      <name>Aclarubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aclarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11618</drugbank-id>
      <name>Zorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Zorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11630</drugbank-id>
      <name>Temoporfin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Temoporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11646</drugbank-id>
      <name>Conatumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Conatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11651</drugbank-id>
      <name>Dactolisib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dactolisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11662</drugbank-id>
      <name>Rabusertib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rabusertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11669</drugbank-id>
      <name>Ortataxel</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ortataxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11678</drugbank-id>
      <name>Treosulfan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Treosulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11688</drugbank-id>
      <name>2-chloroethyl-3-sarcosinamide-1-nitrosourea</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 2-chloroethyl-3-sarcosinamide-1-nitrosourea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11694</drugbank-id>
      <name>Ilorasertib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ilorasertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11714</drugbank-id>
      <name>Durvalumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Durvalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11716</drugbank-id>
      <name>Misonidazole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Misonidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11717</drugbank-id>
      <name>Epacadostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Epacadostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11718</drugbank-id>
      <name>Encorafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Encorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11727</drugbank-id>
      <name>Endostar</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Endostar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11737</drugbank-id>
      <name>Icotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Icotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11752</drugbank-id>
      <name>Bryostatin 1</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bryostatin 1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Talazoparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11771</drugbank-id>
      <name>Tremelimumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tremelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11793</drugbank-id>
      <name>Niraparib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Niraparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11795</drugbank-id>
      <name>GSK-2636771</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with GSK-2636771.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11800</drugbank-id>
      <name>Tivozanib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tivozanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11805</drugbank-id>
      <name>Saracatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Saracatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11812</drugbank-id>
      <name>Talaporfin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Talaporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11830</drugbank-id>
      <name>Mocetinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mocetinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11832</drugbank-id>
      <name>Crenolanib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Crenolanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11841</drugbank-id>
      <name>Entinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Entinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11880</drugbank-id>
      <name>Acridine Carboxamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Acridine Carboxamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11886</drugbank-id>
      <name>Infigratinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Infigratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11891</drugbank-id>
      <name>CUDC-907</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with CUDC-907.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11894</drugbank-id>
      <name>Efatutazone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Efatutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11907</drugbank-id>
      <name>Rociletinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rociletinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11918</drugbank-id>
      <name>Guadecitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Guadecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 6-O-benzylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11945</drugbank-id>
      <name>Avelumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Avelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Binimetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11972</drugbank-id>
      <name>Rilotumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rilotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11973</drugbank-id>
      <name>Tesevatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11999</drugbank-id>
      <name>Vosaroxin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vosaroxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Abemaciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alpelisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12028</drugbank-id>
      <name>Broxuridine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Broxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12036</drugbank-id>
      <name>Naquotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Naquotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12056</drugbank-id>
      <name>Trebananib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trebananib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12081</drugbank-id>
      <name>Anecortave</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Anecortave.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12082</drugbank-id>
      <name>Vesnarinone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vesnarinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12083</drugbank-id>
      <name>Mafosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mafosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12085</drugbank-id>
      <name>LCL-161</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with LCL-161.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12108</drugbank-id>
      <name>Taselisib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Taselisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12124</drugbank-id>
      <name>Namitecan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Namitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lorlatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gilteritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12142</drugbank-id>
      <name>Duligotuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Duligotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12146</drugbank-id>
      <name>Rigosertib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rigosertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12156</drugbank-id>
      <name>Cordycepin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cordycepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12174</drugbank-id>
      <name>CUDC-101</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with CUDC-101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12182</drugbank-id>
      <name>Binetrakin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Binetrakin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12185</drugbank-id>
      <name>Exatecan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Exatecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12202</drugbank-id>
      <name>Zalutumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Zalutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12222</drugbank-id>
      <name>Lurtotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lurtotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12232</drugbank-id>
      <name>KRN-7000</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with KRN-7000.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12257</drugbank-id>
      <name>Platinum</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Platinum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12259</drugbank-id>
      <name>CG-200745</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with CG-200745.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12266</drugbank-id>
      <name>Epofolate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Epofolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12279</drugbank-id>
      <name>OBP-801</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with OBP-801.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12340</drugbank-id>
      <name>Navitoclax</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Navitoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12352</drugbank-id>
      <name>Bizelesin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bizelesin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12376</drugbank-id>
      <name>Ricolinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ricolinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12379</drugbank-id>
      <name>Indirubin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Indirubin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12381</drugbank-id>
      <name>Merestinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Merestinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12382</drugbank-id>
      <name>R-306465</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with R-306465.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12385</drugbank-id>
      <name>10-hydroxycamptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 10-hydroxycamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12391</drugbank-id>
      <name>Sagopilone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sagopilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12422</drugbank-id>
      <name>Sulforaphane</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sulforaphane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12459</drugbank-id>
      <name>Belotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Belotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12473</drugbank-id>
      <name>Taurolidine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Taurolidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Copanlisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12498</drugbank-id>
      <name>Mogamulizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mogamulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12515</drugbank-id>
      <name>9-aminocamptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 9-aminocamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12525</drugbank-id>
      <name>Molgramostim</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Molgramostim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12539</drugbank-id>
      <name>Oltipraz</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oltipraz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12549</drugbank-id>
      <name>Pyrazoloacridine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pyrazoloacridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12565</drugbank-id>
      <name>Abexinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Abexinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12577</drugbank-id>
      <name>Fosbretabulin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fosbretabulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12589</drugbank-id>
      <name>Dacetuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dacetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12593</drugbank-id>
      <name>Apaziquone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Apaziquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12596</drugbank-id>
      <name>Combretastatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Combretastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12637</drugbank-id>
      <name>Onapristone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Onapristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12638</drugbank-id>
      <name>PU-H71</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with PU-H71.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12645</drugbank-id>
      <name>Givinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Givinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12671</drugbank-id>
      <name>Beloranib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Beloranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12677</drugbank-id>
      <name>Soblidotin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Soblidotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12681</drugbank-id>
      <name>Salirasib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Salirasib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12688</drugbank-id>
      <name>Moxetumomab Pasudotox</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Moxetumomab Pasudotox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12695</drugbank-id>
      <name>Phenethyl Isothiocyanate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Phenethyl Isothiocyanate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12697</drugbank-id>
      <name>Methylselenocysteine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methylselenocysteine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12701</drugbank-id>
      <name>Intetumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Intetumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12730</drugbank-id>
      <name>Dolastatin 10</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dolastatin 10.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12736</drugbank-id>
      <name>Etanidazole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etanidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12769</drugbank-id>
      <name>Lometrexol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lometrexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12797</drugbank-id>
      <name>Ecromeximab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ecromeximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12832</drugbank-id>
      <name>Prednimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Prednimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12870</drugbank-id>
      <name>Buthionine Sulfoximine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Buthionine Sulfoximine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12873</drugbank-id>
      <name>Dianhydrogalactitol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dianhydrogalactitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12881</drugbank-id>
      <name>Indole-3-carbinol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Indole-3-carbinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12901</drugbank-id>
      <name>Fiacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fiacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12912</drugbank-id>
      <name>Nolatrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nolatrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12916</drugbank-id>
      <name>Mitolactol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitolactol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12920</drugbank-id>
      <name>Pinometostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pinometostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12948</drugbank-id>
      <name>Didox</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Didox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12967</drugbank-id>
      <name>Mitoguazone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitoguazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pexidartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12987</drugbank-id>
      <name>Penclomedine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Penclomedine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13005</drugbank-id>
      <name>Rebastinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rebastinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13046</drugbank-id>
      <name>Tocladesine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tocladesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13066</drugbank-id>
      <name>Liarozole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Liarozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13069</drugbank-id>
      <name>Nimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13104</drugbank-id>
      <name>X-396</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with X-396.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13128</drugbank-id>
      <name>Sizofiran</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sizofiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nedaplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13164</drugbank-id>
      <name>Olmutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olmutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13182</drugbank-id>
      <name>Daidzein</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Daidzein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13243</drugbank-id>
      <name>Tiazofurine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tiazofurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13304</drugbank-id>
      <name>Triaziquone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Triaziquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13318</drugbank-id>
      <name>Demecolcine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Demecolcine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13334</drugbank-id>
      <name>Mannosulfan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mannosulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13339</drugbank-id>
      <name>Etoglucid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etoglucid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13375</drugbank-id>
      <name>Edrecolomab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Edrecolomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13480</drugbank-id>
      <name>Lentinan</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lentinan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13543</drugbank-id>
      <name>Mitobronitol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitobronitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13647</drugbank-id>
      <name>Semustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Semustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13677</drugbank-id>
      <name>Carboquone</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carboquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13767</drugbank-id>
      <name>Vorozole</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vorozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13809</drugbank-id>
      <name>Paclitaxel poliglumex</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel poliglumex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13811</drugbank-id>
      <name>Oblimersen</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oblimersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13832</drugbank-id>
      <name>Ranimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ranimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13877</drugbank-id>
      <name>Iniparib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Iniparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13896</drugbank-id>
      <name>Talimogene laherparepvec</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Talimogene laherparepvec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13912</drugbank-id>
      <name>Coumermycin A1</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Coumermycin A1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13916</drugbank-id>
      <name>Toyocamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Toyocamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14031</drugbank-id>
      <name>Tretamine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14067</drugbank-id>
      <name>Dofequidar</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dofequidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cinnamaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14680</drugbank-id>
      <name>Combretastatin A4</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Combretastatin A4.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14707</drugbank-id>
      <name>Cemiplimab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cemiplimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Larotrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14731</drugbank-id>
      <name>Tagraxofusp</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tagraxofusp.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14765</drugbank-id>
      <name>Rivoceranib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rivoceranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14792</drugbank-id>
      <name>AZD-5991</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with AZD-5991.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14844</drugbank-id>
      <name>ONC-201</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with ONC-201.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14860</drugbank-id>
      <name>Ensartinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ensartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14865</drugbank-id>
      <name>Human interleukin-2</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Human interleukin-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14877</drugbank-id>
      <name>Lintuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lintuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14947</drugbank-id>
      <name>Bermekimab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bermekimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14951</drugbank-id>
      <name>Etirinotecan pegol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etirinotecan pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14999</drugbank-id>
      <name>Human interferon beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Human interferon beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15035</drugbank-id>
      <name>Zanubrutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Zanubrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15057</drugbank-id>
      <name>NUC-1031</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with NUC-1031.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15157</drugbank-id>
      <name>Voruciclib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Voruciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15215</drugbank-id>
      <name>KRN-5500</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with KRN-5500.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15289</drugbank-id>
      <name>Perillyl alcohol</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Perillyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15321</drugbank-id>
      <name>Tefinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tefinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Biochanin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15351</drugbank-id>
      <name>Dihematoporphyrin ether</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dihematoporphyrin ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15366</drugbank-id>
      <name>SOR-C13</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with SOR-C13.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15383</drugbank-id>
      <name>Pidilizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pidilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15419</drugbank-id>
      <name>Nanatinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nanatinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15466</drugbank-id>
      <name>Tallimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tallimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12062</drugbank-id>
      <name>Volasertib</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Volasertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of pulmonary toxicity can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00019</drugbank-id>
      <name>Pegfilgrastim</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00061</drugbank-id>
      <name>Pegademase</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegademase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01839</drugbank-id>
      <name>Propylene glycol</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Propylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03394</drugbank-id>
      <name>Heptaethylene glycol</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegaptanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05202</drugbank-id>
      <name>Egaptivon pegol</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Egaptivon pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05321</drugbank-id>
      <name>PEG-uricase</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05860</drugbank-id>
      <name>Peginterferon alfacon-1</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginterferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06022</drugbank-id>
      <name>GlycoPEG-GCSF</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with GlycoPEG-GCSF.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06293</drugbank-id>
      <name>Pegnivacogin</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06325</drugbank-id>
      <name>Pegpleranib</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegpleranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06611</drugbank-id>
      <name>Pegsunercept</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegsunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06811</drugbank-id>
      <name>Polidocanol</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginesatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11661</drugbank-id>
      <name>Eptacog alfa pegol (activated)</name>
      <description>The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11707</drugbank-id>
      <name>Olaptesed Pegol</name>
      <description>The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12258</drugbank-id>
      <name>Abicipar Pegol</name>
      <description>The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12578</drugbank-id>
      <name>Lexaptepid Pegol</name>
      <description>The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12839</drugbank-id>
      <name>Pegvaliase</name>
      <description>The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12842</drugbank-id>
      <name>Pegamotecan</name>
      <description>The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14712</drugbank-id>
      <name>Elapegademase</name>
      <description>The therapeutic efficacy of Elapegademase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00984</drugbank-id>
      <name>Nandrolone phenpropionate</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be increased when used in combination with Nandrolone phenpropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08804</drugbank-id>
      <name>Nandrolone decanoate</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be increased when used in combination with Nandrolone decanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13169</drugbank-id>
      <name>Nandrolone</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be increased when used in combination with Nandrolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05168</drugbank-id>
      <name>Vintafolide</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vintafolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinflunine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vincamine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20205</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910408</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Methoxy_polyethylene_glycol-epoetin_beta</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000654</id>
      <name>Erythropoietin receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>stimulator</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P19235" source="Swiss-Prot">
        <name>Erythropoietin receptor</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.</specific-function>
        <gene-name>EPOR</gene-name>
        <locus>19p13.3-p13.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>251-273</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>4.37</theoretical-pi>
        <molecular-weight>55064.725</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3416</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>EPOR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M60459</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182245</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1718</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P19235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EPOR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>EPO-R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001304|Erythropoietin receptor
MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL
ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY
EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH
KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG
SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS
AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
SDGPYSNPYENSLIPAAEPLPPSYVACS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010455|Erythropoietin receptor (EPOR)
ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT
GGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC
TTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG
GTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC
TACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT
GGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA
GAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT
GAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC
CACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC
GAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG
GGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC
CGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG
TCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG
GTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG
AAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC
AAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC
ACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG
ACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC
AGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG
CCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC
TCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT
GCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA
CTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT
GACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA
TCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG
CCCCCCAGCTATGTGGCTTGCTCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00041</identifier>
            <name>fn3</name>
          </pfam>
          <pfam>
            <identifier>PF09067</identifier>
            <name>EpoR_lig-bind</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>erythropoietin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>decidualization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>erythropoietin-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>